

Claims

1. A pharmaceutical composition containing at least one platinum complex with a secondary xanthate.
2. The pharmaceutical composition of claim 1 containing at least one of the following compounds:
Bis(O-isopropyl-dithiocarbonato)platinum(II), Bis(O-(1-ethyl)propyl-dithiocarbonato)platinum(II), Bis(O-(1,2,2-trimethyl)propyl-dithiocarbonato)platinum(II), Bis(O-cyclobutyl-dithiocarbonato)platinum(II), Bis(O-cyclopentyl-dithiocarbonato)platinum(II) and/or Bis(O-cyclohexyl-dithiocarbonato)platinum(II).
3. The pharmaceutical composition according to claim 1 or 2, comprising additionally one or more of the following compounds: cyclosporine, rapamycin, 15-desoxyspergualin, OKT3 and/or azothioprine.
4. The pharmaceutical composition according to claim 1, 2 or 3, comprising additionally a cytokine, interferon and/or a further cytostatic agent.
5. The pharmaceutical composition according to claim 4, wherein the additional cytostatic agent is methotrexate, aminopterin, dacarbazine, nitroso urea compounds, fluorouracil, bleomycin, daunomycin, daunorubicin, doxorubicin, mithramycin, mitomycin C.
6. Use of at least one platinum complex with a secondary xanthate for preparing a pharmaceutical composition for treating a cancerous or an autoimmune disease.

7. Use of claim 6 wherein the pharmaceutical composition contains at least one of the following compounds:

Bis(O-isopropyl-dithiocarbonato)platinum(II), Bis(O-(1-ethyl)propyl-dithiocarbonato)platinum(II), Bis(O-(1,2,2-trimethyl)propyl-dithiocarbonato)platinum(II), Bis(O-cyclobutyl-dithiocarbonato)platinum(II), Bis(O-cyclopentyl-dithiocarbonato)platinum(II) and/or Bis(O-cyclohexyl-dithiocarbonato)platinum(II).

8. Use according to claim 6 or 7, wherein the cancerous disease is selected from testicular tumors, ovarian carcinomas, bladder carcinomas, colon carcinomas, prostatic carcinomas, parvocellular and non-parvocellular bronchial carcinomas, carcinomas of the cephalic and cervical parts, carcinomas of the thoracic and abdominal regions, cervical and endometrial carcinomas, sarcomas, melanomas and leukemias.

9. A process for the production of a pharmaceutical composition according to any one of claims 1 to 5, characterized in that a compound as defined in claim 1 or 2 and, optionally, one or more of the compounds as defined in any one of claims 3 to 5 are mixed with a pharmaceutically compatible carrier or diluent.